Article
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Nov 2020
Papadimitrakopoulou V A, Mok T S, Han J-Y, Ahn M-J, Delmonte A, Ramalingam S S, Kim S W, Shepherd F A, Laskin J, He Y, Akamatsu H, Theelen W S M E, Su W-C, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu Y-L
Abstract excerpt
BACKGROUND: In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis. PATIENTS AND METHODS: Adult...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.